Sacituzumab govitecan-hziy
Products billed under this code include Trodelvy.
Payment limit per 2.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Trodelvy.
Payment limit per 2.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Trodelvy | Immunomedics, Inc. | 55135-0132-01 | 72 | $2,702.592 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $37.536 | −$0.104 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted September 17, 2026 |
| 3Q26 | $37.64 | +$0.843 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted September 15, 2026 |
| 2Q26 | $36.797 | −$0.185 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted September 15, 2026 |
| 1Q26 | $36.982 | +$0.706 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted September 15, 2026 |
| 4Q25 | $36.276 | +$0.018 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted September 8, 2026 |
| 3Q25 | $36.258 | +$0.458 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted March 10, 2026 |
| 2Q25 | $35.80 | +$0.362 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted March 10, 2026 |
| 1Q25 | $35.438 | +$0.77 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted December 19, 2025 |
| 4Q24 | $34.668 | −$0.017 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 11, 2025 |
| 3Q24 | $34.685 | +$0.811 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 11, 2025 |
| 2Q24 | $33.874 | −$0.077 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted March 11, 2025 |
| 1Q24 | $33.951 | +$0.843 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted December 19, 2024 |
| 4Q23 | $33.108 | −$0.207 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted October 10, 2024 |
| 3Q23 | $33.315 | +$0.763 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 5, 2024 |
| 2Q23 | $32.552 | −$0.03 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted February 23, 2024 |
| 1Q23 | $32.582 | +$0.546 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted December 6, 2023 |
| 4Q22 | $32.036 | +$0.003 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 22, 2023 |
| 3Q22 | $32.033 | +$0.775 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 9, 2023 |
| 2Q22 | $31.258 | $0.00 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted December 14, 2022 |
| 1Q22 | $31.258 | +$0.904 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 8, 2022 |
| 4Q21 | $30.354 | −$0.011 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 2, 2022 |
| 3Q21 | $30.365 | +$0.877 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted June 2, 2022 |
| 2Q21 | $29.488 | −$0.017 | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted March 1, 2022 |
| 1Q21 | $29.505 | – | 2.5 MG | Sacituzumab govitecan-hziy | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.